XBB1.5 Variant Vaccine – Chasing the Rainbow

XBB1.5 Variant Vaccine FI
Photo Credit - © Canva Pro Content License

Medsafe recently granted full approval to a new monovalent Pfizer Comirnaty vaccine against XBB1.5. This variant was first mentioned in NZ media over a year ago in Oct 2022.

In a December 2023 MoH* press release announcing the approval of the new vaccine, Chris James of Medsafe is reported to have said:

Following a robust and efficient approval process the vaccine will be used to help reduce next year’s winter load on our hospitals”, he says. “The series of changes we see in the COVID-19 virus means we need to continually reassess and update our response to it.”

To gain approval for the new injection in the United States, Pfizer presented data to the ACIP* meeting at the CDC* in Sept 2023.  The research behind the new injection was discussed.  Prior to it being administered in humans, it was tested as both a booster and as a primary series, on 10 mice per study group.

XBB1.5 Variant Vaccine ACIP 10 mice
Image captured for criticism/review and reporting current events under Fair Dealing – The Copyright Act 1994

Is it safe?

The Australian institution ATAGI* has approved XBB1.5 for use in their country but have noted some deficiencies.

“Vaccine effectiveness and safety of XBB.1.5-containing vaccines have been largely inferred from earlier COVID-19 vaccine formulations. Limited direct data are available.”

“ATAGI has no additional safety concerns regarding the use of XBB.1.5-containing vaccines compared to older vaccine formulations.

The wording is interesting – ‘no additional safety concerns’.  What do they mean?  From our perspective there are already far too many safety concerns from the previous Pfizer versions.  So many by the end of the first three months post-marketing surveillance in early 2021, that the product should never have been released in NZ.

Will Variant XBB1.5 Be Relevant Come Winter 2024?

According to the NZ ESR* ‘COVID-19 Genomics Insights Dashboard (CGID) #44’ of 8 Dec 2023:

The XBB.1.5 and XBB.1.16 lineages are decreasing and are no longer included in the tracked variants for this report.

A graph of the different variants currently in NZ, at the end of 2023 was included in the report.  As can be seen, the lime green XBB variant now accounts for only a very small proportion of the covid cases the country is experiencing.

XBB1.5 variants in circulation
Image captured for criticism/review and reporting current events under Fair Dealing – The Copyright Act 1994

It is highly likely that the XBB1.5 variant will no longer be circulating when next winter arrives and the new booster will be as useless as the prior ones in preventing anything, and no less dangerous.

We also note that the current bivalent booster is supposedly effective against BA4 (not featuring on the graph) and BA5 (such a small proportion as to be nearly invisible).  It is impossible to keep ahead of this situation with concoctions manufactured in laboratories. This has been predicted, and proven, from the start.

Our opinion is that the best defence a person has is a healthy, robust immune system, rather than an endless series of artificial ‘updates’.  In this recent paper, we are shown once again that natural infection, especially with the omicron variants, is the most protective against severe outcomes, and that vaccination backfired, increasing risk of hospitalisation. Of course, whatever benefits “hybrid immunity” brings (after having vaccination and infection), the injections are known to genetically modify the recipient. And unlikely in a good, choose-your-superpower kind of way.

But then there is this mischievous research from two of Japan’s top experts, showing that the major “variants” have hallmarks of genetic engineering all over them. They wonder if the whole thing is a scam to rort the taxpayers of the world for endless new jab formulations.

Perhaps the only rainbow we should be searching for is the rotten trout. Something sure smells bad.

*Glossary

MOH

Ministry of Health

ACIP

Advisory Committee on Immunisation Practices – in the US

CDC

Centers for Disease Control

ATAGI

Australian Technical Advisory Group on Immunisation

ESR

The Institute of Environmental Science and Research

Click to rate this post!
[Total: 52 Average: 4.8]
Share this post

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *